Bupivacaine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Bupivacaine: From Dermatitis to Acrodermatitis Chronica Atrophicans
One-Sentence Summary
Bupivacaine is a long-acting local anaesthetic, listed in the knowledge graph used by the model with dermatitis as its original indication. The TxGNN model predicts it may be effective for acrodermatitis chronica atrophicans, but no clinical trials and no publications currently support this prediction. The high score is a computational result only and has no supporting mechanism or clinical evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Dermatitis (from the knowledge graph; the Singapore licence records contain no indication text) |
| Predicted New Indication | Acrodermatitis chronica atrophicans |
| TxGNN Prediction Score | 99.23% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 4 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. Bupivacaine is a local anaesthetic of the amide class and is generally understood to block sodium channels in nerves. It is used for nerve blocks, infiltration and spinal anaesthesia, not as a disease-modifying treatment for skin conditions.
Acrodermatitis chronica atrophicans is a late-stage skin infection caused by Borrelia. A local anaesthetic has no plausible way to treat the infection itself. At most it could relieve local pain or neuropathic symptoms. The high score probably reflects closeness to dermatitis-related nodes in the knowledge graph rather than a true biological link.
The other top-ranked predictions show the same pattern. Dermatomyositis variants, connective tissue disease-associated lung disease, acne keloid, familial hydroa vacciniforme and middle ear polyp have no clinical or literature evidence and no plausible mechanism.
Predictions with some evidence (uterine polyp, epulis, vocal cord polyp) concern bupivacaine as procedural anaesthesia or a co-injected agent. They do not show that it treats the disease itself.
Clinical Trial Evidence
Currently no related clinical trials are registered for acrodermatitis chronica atrophicans.
For context, trials found for lower-ranked predictions are all procedural and not disease treatment:
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT05967936 | Not applicable | Unknown | 242 | Compares types of local anaesthesia in outpatient hysteroscopy (uterine polyp); concerns anaesthetic technique, not polyp treatment |
| NCT06734975 | Phase 2 | Recruiting | 28 | Superior laryngeal nerve block vs saline during laryngoscopy for benign vocal fold lesions; endpoints are perioperative cough, pain and voice, no results yet |
Literature Evidence
Currently no related literature is available for acrodermatitis chronica atrophicans.
For context, publications found for lower-ranked predictions are indirect:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22070928 | 2012 | Case series | J Minim Invasive Gynecol | Low-dose spinal anaesthesia with hyperbaric bupivacaine and fentanyl for operative hysteroscopy in high-risk patients |
| 11862204 | 2002 | Case series | Oral Surg Oral Med Oral Pathol Oral Radiol Endod | Intralesional corticosteroid mixed with bupivacaine or lidocaine for central giant cell granuloma; the effect comes from the corticosteroid |
| 19941766 | 2009 | Case series | J Dent Child | Intralesional corticosteroid injection for central giant cell granuloma in a child |
| 29750618 | 2018 | Case report | J Clin Pediatr Dent | Modified technique for central giant cell lesion in children, with intralesional corticosteroid |
| 16910145 | 2006 | Case report | Rev Esp Anestesiol Reanim | Transient neurological syndrome after spinal hyperbaric bupivacaine following polyp removal (an adverse event) |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN05681P | MARCAIN SPINAL 0.5% HEAVY INJECTION | Injection | Not stated in the compiled data |
| SIN05679P | MARCAIN INJECTION 0.5% (POLYAMP DUOFIT) | Injection | Not stated in the compiled data |
| SIN13211P | Marcain Injection 0.5% (4ml) | Injection | Not stated in the compiled data |
| SIN14273P | SURGICAINE Injection | Injection | Not stated in the compiled data |
All four licences are valid single-ingredient injectable products. No topical formulation is registered.
Safety Considerations
Contraindications suggested by the knowledge graph (these are graph associations, not package insert text):
- Cardiovascular: hypertension, hypotension, coronary artery disease, myocardial infarction, atrial fibrillation, heart conduction disease, sudden cardiac arrest
- Hepatic and renal: liver failure, liver disease, kidney disease, gallbladder disease
- Respiratory: chronic obstructive pulmonary disease, respiratory failure
- Metabolic and endocrine: diabetes mellitus, diabetic ketoacidosis, hypothyroidism, potassium deficiency
- Other: epilepsy, angle-closure glaucoma, inflammatory bowel disease, benign prostatic hyperplasia, hemoglobinopathy, substance abuse/dependence
Drug Interactions: 56 interactions were recorded. Those with a graded level are moderate, with aprepitant and liposomal morphine. The rest have no graded level, including proton pump inhibitors (pantoprazole, omeprazole, lansoprazole), corticosteroids (dexamethasone, prednisone, hydrocortisone, prednisolone, triamcinolone), ondansetron, metoclopramide, famotidine, ranitidine, simvastatin, vancomycin, metronidazole, atropine, naloxone and potassium chloride.
Please also refer to the package insert for full warnings and contraindications. Bupivacaine is myotoxic and has been associated with transient neurological syndrome after spinal use, as shown in the literature above.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is a model output only (L5), with no trials or publications for acrodermatitis chronica atrophicans. A local anaesthetic has no plausible disease-modifying mechanism against a Borrelia skin infection. The other top-ranked predictions are also unsupported or only procedurally related.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA (currently missing and blocking safety screening)
- Mechanism of action data
- Evidence of a plausible mechanism or clinical benefit in the predicted indication (beyond symptomatic pain relief)
- Clarification of the original indication, since the licence records contain no approved indication text and "dermatitis" comes only from the knowledge graph
- Route and formulation compatibility assessment, since all registered products are injectables
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.